In today’s session Esperion Therapeutics Inc (ESPR) registered an unusually high (201) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious ESPR increase. With 201 contracts traded and 2234 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: ESPR161021C00013000 closed last at: $1.9 or 7.3% down. About 142,134 shares traded hands. Esperion Therapeutics Inc (NASDAQ:ESPR) has declined 25.26% since March 2, 2016 and is downtrending. It has underperformed by 33.52% the S&P500.
Analysts await Esperion Therapeutics Inc (NASDAQ:ESPR) to report earnings on November, 3. They expect $-0.88 EPS, down 54.39% or $0.31 from last year’s $-0.57 per share. After $-0.62 actual EPS reported by Esperion Therapeutics Inc for the previous quarter, Wall Street now forecasts 41.94% negative EPS growth.
Esperion Therapeutics Inc (NASDAQ:ESPR) Ratings Coverage
Out of 13 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 7 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 54% are positive. $130.0 is the highest target while $10 is the lowest. The $33.25 average target is 135.82% above today’s ($14.1) stock price. Esperion Therapeutics has been the topic of 30 analyst reports since July 28, 2015 according to StockzIntelligence Inc. As per Wednesday, June 29, the company rating was downgraded by RBC Capital Markets. As per Wednesday, June 29, the company rating was downgraded by Barclays Capital. The rating was initiated by WallachBeth Capital on Monday, October 26 with “Buy”. On Friday, August 7 the stock rating was maintained by Chardan Capital Markets with “Sell”. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) earned “Buy” rating by Needham on Monday, August 10. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) earned “Buy” rating by Lake Street on Wednesday, June 29. The firm has “Outperform” rating by RBC Capital Markets given on Friday, November 6. The firm earned “Overweight” rating on Wednesday, February 24 by Barclays Capital. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) has “Hold” rating given on Friday, September 4 by Zacks. The rating was maintained by Needham with “Buy” on Thursday, June 30.
According to Zacks Investment Research, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.”
Insitutional Activity: The institutional sentiment increased to 1.27 in 2016 Q2. Its up 0.11, from 1.16 in 2016Q1. The ratio increased, as 13 funds sold all Esperion Therapeutics Inc shares owned while 24 reduced positions. 9 funds bought stakes while 38 increased positions. They now own 14.43 million shares or 7.41% less from 15.58 million shares in 2016Q1.
Equitec Proprietary Mkts Ltd Limited Liability Company holds 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR) for 300 shares. Wells Fargo And Mn owns 21,860 shares or 0% of their US portfolio. Barclays Plc has 388 shares for 0% of their US portfolio. Gilder Gagnon Howe & Communications Ltd Liability Com holds 0% or 3,830 shares in its portfolio. Pentwater Capital Mgmt L P owns 1.52 million shares or 0.2% of their US portfolio. Interest Group Inc Inc accumulated 0% or 8,240 shares. Moreover, United Services Automobile Association has 0% invested in Esperion Therapeutics Inc (NASDAQ:ESPR) for 35,280 shares. California Public Employees Retirement Sys reported 49,300 shares or 0% of all its holdings. Swiss Natl Bank holds 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR) for 22,200 shares. Stifel Fin owns 15,017 shares or 0% of their US portfolio. Bvf Il accumulated 499,142 shares or 1.05% of the stock. Us Fincl Bank De last reported 15,320 shares in the company. The United Kingdom-based Oxford Asset Mngmt has invested 0.1% in Esperion Therapeutics Inc (NASDAQ:ESPR). Bnp Paribas Arbitrage Sa owns 565 shares or 0% of their US portfolio. Aisling Cap Limited Com owns 1.64 million shares or 3.82% of their US portfolio.
Esperion Therapeutics, Inc. is a pharmaceutical company. The company has a market cap of $313.82 million. The Firm is focused on developing and commercializing oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with elevated LDL-C. It currently has negative earnings. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
ESPR Company Profile
Esperion Therapeutics, Inc., incorporated on January 22, 2008, is a pharmaceutical company. The Firm is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Firm is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins.
More notable recent Esperion Therapeutics Inc (NASDAQ:ESPR) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on November 22, 2013, also Fool.com with their article: “Esperion Therapeutics Inc Sinks After FDA Says, “Ask Us in 2019″” published on June 29, 2016, Fool.com published: “Why Esperion Therapeutics, Inc. Stock Cratered Today” on September 29, 2015. More interesting news about Esperion Therapeutics Inc (NASDAQ:ESPR) were released by: Finance.Yahoo.com and their article: “Esperion Therapeutics (ESPR) in Focus: Stock Jumps 18.1%” published on September 21, 2016 as well as Prnewswire.com‘s news article titled: “Shareholder Class Action Filed Against Esperion Therapeutics, Inc. – ESPR” with publication date: January 14, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.